2 citations
,
September 2009 in “Pigment Cell & Melanoma Research” This study found that non-cutaneous melanocytes in mice are less sensitive to Kit signaling compared to cutaneous melanocytes, showing dependence on ET3 and HGF signaling.
4 citations
,
May 2024 in “Experimental Dermatology” This study reviews the role of the KIT ligand and receptor pathway in managing melanocyte and mast cell-related skin diseases, examining how its regulation can lead to potential therapies for conditions like vitiligo, melanoma, and mastocytosis. Results are not reported.
67 citations
,
November 2019 in “Nature Communications” This study demonstrated that a c-Kit-CreER-driven mouse model confirms melanocyte stem cells as a genuine source of melanoma, paralleling human melanoma in heterogeneity and gene signatures.
April 2023 in “Journal of Investigative Dermatology” In this study, topical inhibition of casein kinase 1 in mice was found to enhance melanocyte precursor migration and eumelanin production, suggesting potential applications for treating vitiligo and graying hair through KitL/c-Kit signaling pathway activation.
January 2005 in “Enlighten: Publications (The University of Glasgow)” In this transgenic mouse study, preliminary findings suggest that overt melanocyte hyperplasia may require prior keratinocyte hyperplasia, indicating a potential role for keratinocyte mutation in early melanoma development.